Benzinga | Jun 11, 2021 06:30AM EDT

HC Wainwright & Co. Initiates Coverage On Intellia Therapeutics with Buy Rating, Announces Price Target of $111

HC Wainwright & Co. analyst Michael King initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Buy rating and announces Price Target of $111.